Hormone replacement therapy and risk of colon and rectal cancer

Esteve Fernandez, Carlo La Vecchia, Claudia Braga, Renato Talamini, Eva Negri, Fabio Parazzini, Silvia Franceschi

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

The hypothesis that sex hormones may influence colorectal cancer risk was formulated in the early 1980s, but epidemiological studies on a relationship between colorectal cancer risk and hormone replacement therapy (HRT) have only accumulated over the last few years. To investigate the relationship between HRT and colon and rectal cancer and the role of other covariates that might modify it, we analyzed combined data from two case- control studies conducted in Italy between 1985 and 1996, including 994 women with incident colon cancer, 542 with rectal cancer, and 3110 controls with acute, non-neoplastic, nondigestive, non-hormone-related disorders. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from unconditional multiple logistic regression equations including terms for age, center/study period, education, family history of colorectal cancer, status and age at menopause, parity, use of oral contraceptives, total energy intake, and body mass index. Ever use of HRT was inversely associated with cancer of the colon (OR = 0.64, 95% CI = 0.46-0.88) and of the rectum (OR = 0.46, 95% CI = 0.29-0.72). Increasing duration of use of HRT was related to decreasing risk for colon and rectal cancers (P for trend <0.01). No interaction emerged, and the inverse association persisted across separate strata of other risk factors. This study, one of the largest case-control investigations on exogenous female hormones and colorectal cancer thus far, provides further evidence that women who have ever used HRT are at lower risk of colon and rectal cancer. Because colorectal cancer is the second most common neoplasm and cause of death among nonsmoking women in developed countries, these results may have a major public health impact.

Original languageEnglish
Pages (from-to)329-333
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume7
Issue number4
Publication statusPublished - Apr 1998

Fingerprint

Hormone Replacement Therapy
Rectal Neoplasms
Colonic Neoplasms
Colorectal Neoplasms
Odds Ratio
Confidence Intervals
Gonadal Steroid Hormones
Oral Contraceptives
Menopause
Parity
Energy Intake
Developed Countries
Rectum
Italy
Case-Control Studies
Epidemiologic Studies
Cause of Death
Body Mass Index
Public Health
Logistic Models

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Fernandez, E., La Vecchia, C., Braga, C., Talamini, R., Negri, E., Parazzini, F., & Franceschi, S. (1998). Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiology Biomarkers and Prevention, 7(4), 329-333.

Hormone replacement therapy and risk of colon and rectal cancer. / Fernandez, Esteve; La Vecchia, Carlo; Braga, Claudia; Talamini, Renato; Negri, Eva; Parazzini, Fabio; Franceschi, Silvia.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 7, No. 4, 04.1998, p. 329-333.

Research output: Contribution to journalArticle

Fernandez, E, La Vecchia, C, Braga, C, Talamini, R, Negri, E, Parazzini, F & Franceschi, S 1998, 'Hormone replacement therapy and risk of colon and rectal cancer', Cancer Epidemiology Biomarkers and Prevention, vol. 7, no. 4, pp. 329-333.
Fernandez E, La Vecchia C, Braga C, Talamini R, Negri E, Parazzini F et al. Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiology Biomarkers and Prevention. 1998 Apr;7(4):329-333.
Fernandez, Esteve ; La Vecchia, Carlo ; Braga, Claudia ; Talamini, Renato ; Negri, Eva ; Parazzini, Fabio ; Franceschi, Silvia. / Hormone replacement therapy and risk of colon and rectal cancer. In: Cancer Epidemiology Biomarkers and Prevention. 1998 ; Vol. 7, No. 4. pp. 329-333.
@article{5cf42998370b40adb49eece226a00d39,
title = "Hormone replacement therapy and risk of colon and rectal cancer",
abstract = "The hypothesis that sex hormones may influence colorectal cancer risk was formulated in the early 1980s, but epidemiological studies on a relationship between colorectal cancer risk and hormone replacement therapy (HRT) have only accumulated over the last few years. To investigate the relationship between HRT and colon and rectal cancer and the role of other covariates that might modify it, we analyzed combined data from two case- control studies conducted in Italy between 1985 and 1996, including 994 women with incident colon cancer, 542 with rectal cancer, and 3110 controls with acute, non-neoplastic, nondigestive, non-hormone-related disorders. Odds ratios (ORs) and 95{\%} confidence intervals (CIs) were derived from unconditional multiple logistic regression equations including terms for age, center/study period, education, family history of colorectal cancer, status and age at menopause, parity, use of oral contraceptives, total energy intake, and body mass index. Ever use of HRT was inversely associated with cancer of the colon (OR = 0.64, 95{\%} CI = 0.46-0.88) and of the rectum (OR = 0.46, 95{\%} CI = 0.29-0.72). Increasing duration of use of HRT was related to decreasing risk for colon and rectal cancers (P for trend <0.01). No interaction emerged, and the inverse association persisted across separate strata of other risk factors. This study, one of the largest case-control investigations on exogenous female hormones and colorectal cancer thus far, provides further evidence that women who have ever used HRT are at lower risk of colon and rectal cancer. Because colorectal cancer is the second most common neoplasm and cause of death among nonsmoking women in developed countries, these results may have a major public health impact.",
author = "Esteve Fernandez and {La Vecchia}, Carlo and Claudia Braga and Renato Talamini and Eva Negri and Fabio Parazzini and Silvia Franceschi",
year = "1998",
month = "4",
language = "English",
volume = "7",
pages = "329--333",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Hormone replacement therapy and risk of colon and rectal cancer

AU - Fernandez, Esteve

AU - La Vecchia, Carlo

AU - Braga, Claudia

AU - Talamini, Renato

AU - Negri, Eva

AU - Parazzini, Fabio

AU - Franceschi, Silvia

PY - 1998/4

Y1 - 1998/4

N2 - The hypothesis that sex hormones may influence colorectal cancer risk was formulated in the early 1980s, but epidemiological studies on a relationship between colorectal cancer risk and hormone replacement therapy (HRT) have only accumulated over the last few years. To investigate the relationship between HRT and colon and rectal cancer and the role of other covariates that might modify it, we analyzed combined data from two case- control studies conducted in Italy between 1985 and 1996, including 994 women with incident colon cancer, 542 with rectal cancer, and 3110 controls with acute, non-neoplastic, nondigestive, non-hormone-related disorders. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from unconditional multiple logistic regression equations including terms for age, center/study period, education, family history of colorectal cancer, status and age at menopause, parity, use of oral contraceptives, total energy intake, and body mass index. Ever use of HRT was inversely associated with cancer of the colon (OR = 0.64, 95% CI = 0.46-0.88) and of the rectum (OR = 0.46, 95% CI = 0.29-0.72). Increasing duration of use of HRT was related to decreasing risk for colon and rectal cancers (P for trend <0.01). No interaction emerged, and the inverse association persisted across separate strata of other risk factors. This study, one of the largest case-control investigations on exogenous female hormones and colorectal cancer thus far, provides further evidence that women who have ever used HRT are at lower risk of colon and rectal cancer. Because colorectal cancer is the second most common neoplasm and cause of death among nonsmoking women in developed countries, these results may have a major public health impact.

AB - The hypothesis that sex hormones may influence colorectal cancer risk was formulated in the early 1980s, but epidemiological studies on a relationship between colorectal cancer risk and hormone replacement therapy (HRT) have only accumulated over the last few years. To investigate the relationship between HRT and colon and rectal cancer and the role of other covariates that might modify it, we analyzed combined data from two case- control studies conducted in Italy between 1985 and 1996, including 994 women with incident colon cancer, 542 with rectal cancer, and 3110 controls with acute, non-neoplastic, nondigestive, non-hormone-related disorders. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from unconditional multiple logistic regression equations including terms for age, center/study period, education, family history of colorectal cancer, status and age at menopause, parity, use of oral contraceptives, total energy intake, and body mass index. Ever use of HRT was inversely associated with cancer of the colon (OR = 0.64, 95% CI = 0.46-0.88) and of the rectum (OR = 0.46, 95% CI = 0.29-0.72). Increasing duration of use of HRT was related to decreasing risk for colon and rectal cancers (P for trend <0.01). No interaction emerged, and the inverse association persisted across separate strata of other risk factors. This study, one of the largest case-control investigations on exogenous female hormones and colorectal cancer thus far, provides further evidence that women who have ever used HRT are at lower risk of colon and rectal cancer. Because colorectal cancer is the second most common neoplasm and cause of death among nonsmoking women in developed countries, these results may have a major public health impact.

UR - http://www.scopus.com/inward/record.url?scp=0031927679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031927679&partnerID=8YFLogxK

M3 - Article

C2 - 9568789

AN - SCOPUS:0031927679

VL - 7

SP - 329

EP - 333

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 4

ER -